Search Medical Condition
Please enter condition
Please choose location from dropdown

Schiltigheim, France Clinical Trials

A listing of Schiltigheim, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (452) clinical trials

Platine Avastin and OLAparib in 1st Line

Patients with advanced FIGO stage IIIB - IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance.

Phase

1.53 miles

Learn More »

COsegregation of VARiants in the BRCA1/2 and PALB2 Genes

The BRCA1 and BRCA2 genes are the two major high-risk breast and/or ovarian cancer susceptibility genes. Monoallelic germline mutations that disrupt their normal gene function significantly increase the risk of developing cancer in carriers. The identification of a causal mutation in a proband allows proposing pre-symptomatic testing for the causal ...

Phase N/A

1.53 miles

Learn More »

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

This is a biomedical study of interventional type. The trial will include 270 patients (180 patients in the first cohort and 90 patients in a second cohort) over a period of 3 years + 2 years of follow up. This prospective study will be conduct in patients who will receive ...

Phase

1.53 miles

Learn More »

Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer

The causes of treatment failure and death in cervical cancer are still often linked to a local cancer progression The importance of local control for healing, than the cervix situation in the center of pelvis between bladder and rectum which are sensitive organs to irradiation justify the use of utero-vaginal ...

Phase

1.53 miles

Learn More »

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

Adult medulloblastoma is a rare tumour. The "standard risk " group (complete surgery or residual tumour lower than 1,5 cm2, absence of malignant cells in the cerebrospinal fluid, absence of metastasis, absence of MYC amplification and exclusion of large cells medulloblastoma) concerns, for the adult population, a majority of patients ...

Phase

1.53 miles

Learn More »

Medical and Economic Evaluation for Intermediate-risk Prostate Cancer

The aim of the present phase III study is two-folded: 1) to show a superiority of external beam radiotherapy combined with a brachytherapy boost versus exclusive external beam radiotherapy and 2) to evaluate the economic impact of each treatment. The study includes 33 cancer centres, the inclusion time is of ...

Phase N/A

1.53 miles

Learn More »

EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer

The current standard of first-line chemotherapy in advanced ovarian cancer is the combination of carboplatin AUC 5mg/mL/min and paclitaxel 175 mg.m-. This combination is feasible in selected elderly patients such as those included in prospective trials. These trials, however, include a minority of the elderly population. In wider selection of ...

Phase

1.53 miles

Learn More »

Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification

After diagnosis of Neuroblastoma (NB) or Ganglioneuroblastoma : Frozen tumor sample (cell content 60%) must be sent for genomic profile determination by CGH-array, Blood sample at diagnosis must be sent to evaluate MYCN amplification in plasma, In case of NB with a MYCN amplification, blood sample during treatment and follow-up ...

Phase N/A

1.53 miles

Learn More »

Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

At the same time as these results, triple therapies involving 5FU + oxiplatin + irinotecan have objectively shown a significant increase in overall survival of patients with metastatic pancreatic adenocarcinoma compared to gemcitabine alone (median of 11.1 months versus 6.8 months, HR = 0.57 [0.45 - 0.73] p < 0.0001). ...

Phase

1.53 miles

Learn More »

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Phase

1.53 miles

Learn More »